Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295994 | 0.86 | LMNA (0.47) | TSHRPKMLMNAGAAMAPT | |
| SCHEMBL2295134 | 0.85 | PKM (0.48) | PKMLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2295031 | 0.84 | PKM (0.51) | PKMLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2292379 | 0.83 | TSHR (0.50) | TSHRTP53LMNAGAAMAPT | |
| SCHEMBL2290352 | 0.83 | SMN1; SMN2 (0.48) | PKMLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL2298228 | 0.82 | LMNA (0.47) | PKMLMNAGAAMAPTALDH1A1 | |
| SCHEMBL2292202 | 0.79 | MEN1 (0.50) | TSHRTP53LMNAMAPTALDH1A1 | |
| SCHEMBL1676972 | 0.78 | TP53 (0.53) | TSHRTP53PKMLMNAMAPT | |
| SCHEMBL2291043 | 0.78 | CNR1 (0.53) | LMNAGAAMAPTSMN1; SMN2HTT | |
| SCHEMBL2291074 | 0.78 | LMNA (0.53) | TP53LMNAGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | TSHR 2852/4885TP53 3879/4885PKM 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.